A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

导出 OA

翻译打印收藏纠错

作者： Barbara-Ann,Guinn ^[1] ; Patrick J,Schuler ^[2] ; Hubert,Schrezenmeier ^[3] ; Susanne,Hofmann ^[4] ; Johanna,Weiss ^[5] ; Christiane,Bulach ^[5] ; Marlies,Götz ^[5] ; Jochen,Greiner ^[5]

作者单位： Centre for Biomedicine, Hull York Medical School, University of Hull, Hull HU6 7RX, UK. ^[1] Department of Otorhinolaryngology, University Hospital Ulm, 89081 Ulm, Germany. ^[2] Institute of Transfusion Medicine, University of Ulm and German Red Cross, 89073 Ulm, Germany. ^[3] Department of Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany. ^[4] Department of Internal Medicine III, University Hospital Ulm, 89081 Ulm, Germany. ^[5] Department of Internal Medicine, Diakonie Hospital Stuttgart, 70176 Stuttgart, Germany. ^[6]

关键词 acute myeloid leukemia anti-programmed death 1 (PD-1)immunotherapy lenalidomide leukemia-associated antigens

主题词人类(Humans);T淋巴细胞(T-Lymphocytes);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);免疫疗法(Immunotherapy);免疫(Immunity)

DOI 10.3390/ijms24119285

PMID 37298237

发布时间 2023-06-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交